Real-world longitudinal assessment of anifrolumab in patients with systemic lupus erythematosus: clinical outcomes, safety and modulation of cytokines and neutrophil activity
Alp Temiz, Rita Noversa de Sousa, Janina Schoen, Clara Reichardt, Kathrin Standfest, Andreas Wirsching, Melanie Hagen, Giulia Corte, Marco Muñoz Becerra, Koray Tascilar, Axel J Hueber, Georg Schett, Luis E Muñoz, Filippo Fagni · 2026
Read Real-world longitudinal assessment of anifrolumab in patients with systemic lupus erythematosus: clinical outcomes, safety and modulation of cytokines and neutrophil activity by Alp Temiz, Rita Noversa de Sousa, Janina Schoen, Clara Reichardt, Kathrin Standfest, Andreas Wirsching, Melanie Hagen, Giulia Corte, Marco Muñoz Becerra, Koray Tascilar, Axel J Hueber, Georg Schett, Luis E Muñoz, Filippo Fagni (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13331157.txt.
Description
Alp Temiz and colleagues track real-world use of anifrolumab in lupus over 12 months in a 2026 study. Twenty adults with active disease received the drug every 4 weeks across centres, with checks at baseline and every 3 months. People with active kidney or brain involvement were excluded.
Disease activity scores fell steeply by month 12 in the reported values, and most patients reached low activity state while half reached remission marks. Steroid doses dropped, with most baseline users reaching low daily doses and three stopping fully. Drug persistence at 12 months was 65 percent in the cohort summary. Fifty-five side events arose, four of them serious. Immune markers also calmed.
Catalog record
| CREATOR | Alp Temiz, Rita Noversa de Sousa, Janina Schoen, Clara Reichardt, Kathrin Standfest, Andreas Wirsching, Melanie Hagen, Giulia Corte, Marco Muñoz Becerra, Koray Tascilar, Axel J Hueber, Georg Schett, Luis E Muñoz, Filippo Fagni |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48447 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |